Shorter Pathway, Similar Readiness: Evidence for Accelerated MD Programs

• by Amanda Casagrande, D. Michael Elnicki

• July 8, 2026

Can Belzutifan Improve Adjuvant Therapy?

The phase 3 LITESPARK-022 trial compared adjuvant pembrolizumab plus belzutifan with pembrolizumab plus placebo following resection of clear-cell renal-cell carcinoma.

• by Kathryn Wighton

• July 8, 2026

• 4 min

Development and validation of an interpretable machine learning model for predicting atrial fibrillation risk in middle-aged and older patients with coronary heart disease

• by Feng Chen, Qin Fu, Ling Li, Xiao Zhang, Yongqiong Ge, Jianfei Chen

• July 8, 2026

Machine learning prediction of hypertension integrating polygenic risk scores in inner Eurasian populations

• by Vera Tsvetkova, Aleksandra Denisova, Saleem Mansour, Layal Shaheen, Iskandar Hweijeh, Leushin Artem, Travin Grigorii, Dilya Turkmenova, Liya Valieva, Anna Kim, Dmitrii Kharitonov, Anna Ilinskaya, Maria Poptsova, Valery Ilinsky, Alexander Rakitko

• July 8, 2026